RahrBSG’s Post

Let's talk about "transformation" and how LLS is not just changing the prognosis for blood cancer patients - Kacie Meixel https://lnkd.in/gsmKaBWU #oncodaily #oncology #cancer #bloodcancer

Today, we stand united with millions around the world to raise awareness about lymphoma, a complex and challenging cancer affecting the lymphatic system. At Celerion, we’re deeply committed to advancing cancer research and improving the lives of those impacted by lymphoma. Through innovative clinical trials and groundbreaking research, we’re helping to pave the way for new treatments that offer hope and healing. 💚 Join us in spreading awareness and supporting the fight against lymphoma. Together, we can make a difference. 💚 Read this case study, which highlights Celerion’s bioanalytical support of oncology studies: https://lnkd.in/em2mvpx9 #LymphomaAwareness #ClinicalTrials #CancerResearch #WorldLymphomaAwarenessDay #HopeForACure

September is Blood Cancer Awareness Month! Blood cancers like leukemia, lymphoma, and myeloma affect millions of lives worldwide. This month, we stand together to raise awareness, support those affected, and fuel the fight for a cure. Did you know? Every three (3) minutes, someone in the U.S. is diagnosed with a blood cancer. Early detection can save lives! Join us: Share this post, wear red, and help spread the word! Together, we can make a difference. #GLINIPA #LifeisbetterwithGLIN #BloodCancerAwarenessMonth #StandUpToBloodCancer #SupportTheFight #LeukemiaAwareness #LymphomaAwareness #MyelomaAwareness #CancerAwareness

This September, we’re recognizing all of those who have been affected by leukemia, lymphoma, uterine, ovarian, thyroid, prostate, and childhood cancer. Help us raise awareness this month by sharing this post with your community. Together, we can make a difference. Find information on signs and symptoms of all types of cancer from Dana-Farber Cancer Institute. #UterineCancerAwarenessMonth #ChildhoodCancerAwarenessMonth #OvarianCancerAwarenessMonth #ThyroidCancerAwarenessMonth #ProstateCancerAwarenessMonth #LymphomaAwarenessMonth #LeukemiaAwarenessMonth

Cancer has impacted so many of our lives. That's why my fellow AbbVie colleagues and I are raising awareness and support for those affected by leukemia, lymphoma, and myeloma during #BloodCancerAwarenessMonth. Learn more and discover our “Blood Cancer, Explained” video series: https://lnkd.in/gqRV6r_5 #BCAM #WeAreAbbVie

Do you still need the latest insights from #ASCO24 or #EHA24? It’s not too late to get our EPICS Conference Coverage reports on breast cancer, CAR T, GI malignancies, GU malignancies, leukemia, lung cancer, lymphoma, multiple myeloma, or myelofibrosis. Click and learn more: https://lnkd.in/eGj4rEGF  #ASCO2024 #EHA2024

Our friends at Lymphoma Australia are doing STEPS for Lymphoma throughout March to raise funds & support Australians with lymphoma one STEP at a time. Join the movement and take part. ALLG supports this cause & is committed to conducting clinical blood cancer trials to deliver faster and more advanced treatments to patients with lymphoma. Discover more about these trials by visiting https://lnkd.in/gG4naaug. #ALLG #ALLGtrials #bettertreatmentsbetterlives #clinicaltrials   #bloodcancer #bloodcancerawareness #bloodcancercure #bloodcancers #haematology #haematologyresearch #leukaemiaandlymphoma #myeloma #myelomaawareness

Did you know that non-Hodgkin lymphoma accounts for about 90% of all lymphoma cases diagnosed and according to the American Cancer Society is one of the most common cancers in the U.S. Learn more about non-Hodgkin lymphoma and other cancers here: https://lnkd.in/gHWmf_PH #NonHodgkinLymphoma #LymphomaAwareness #Lymphoma

This article on cancer patients is one of my favorite articles that I have written - Amanda R. Ferraro The Leukemia & Lymphoma Society #Cancer #OncoDaily #Oncology #CancerCare

Ryan Jacobs, the Director of Lymphoma at Levine Cancer Institute - Cleveland, presents in this MEDtalk an update on his research from the EHA 2023 meeting on AZD-0486, a novel CD19/CD3 T-cell engager used in treating relapsed refractory follicular lymphoma. The update includes patient responses and tolerability information, highlighting findings such as high overall response rates, complete remission rates, and low toxicity with the double step-up dosing method. 🔗Follow along as we cover EHA 2024: https://lnkd.in/d8jmcNPw #EHA24 #Lymphoma